MG
RPRX icon

Michael Gelband’s Royalty Pharma RPRX Stock Holding History

Michael Gelband’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-123,562
Closed -$5.93M – 1985
2026
Q1 		$5.93M Buy
+123,562
New +$5.41M 0.05% 383
2025
Q3 		– Sell
-246,638
Closed -$8.89M – 1943
2025
Q2 		$8.89M Buy
+246,638
New +$8.17M 0.08% 266
2025
Q1 		– Sell
-143,601
Closed -$3.66M – 1928
2024
Q4 		$3.66M Buy
+143,601
New +$3.81M 0.03% 530
2024
Q1 		– Sell
-70,607
Closed -$1.98M – 1902
2023
Q4 		$1.98M Sell
70,607
-35,937
-34% -$988K 0.01% 579
2023
Q3 		$2.89M Sell
106,544
-378,654
-78% -$11.2M 0.03% 553
2023
Q2 		$14.9M Buy
485,198
+287,283
+145% +$9.73M 0.12% 163
2023
Q1 		$7.13M Buy
197,915
+38,951
+25% +$1.44M 0.06% 391
2022
Q4 		$6.28M Buy
158,964
+151,917
+2,156% +$6.34M 0.09% 296
2022
Q3 		$283K Buy
+7,047
New +$301K ﹤0.01% 1539
2022
Q2 		– Sell
-93,492
Closed -$3.64M – 2374
2022
Q1 		$3.64M Buy
+93,492
New +$3.67M 0.05% 505
2021
Q3 		– Sell
-105,724
Closed -$4.33M – 2554
2021
Q2 		$4.33M Buy
105,724
+89,128
+537% +$3.79M 0.05% 403
2021
Q1 		$724K Buy
+16,596
New +$787K 0.01% 1118
2020
Q4 		– Sell
-234,190
Closed -$9.85M – 2326
2020
Q3 		$9.85M Buy
234,190
+211,536
+934% +$9.08M 0.2% 93
2020
Q2 		$1.1M Buy
+22,654
New +$1.12M 0.03% 694

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Michael Gelband's RPRX Position: Q2 2026 in Review

Michael Gelband sold out of Royalty Pharma (RPRX) in Q2 2026, closing a stake of 123,562 shares — an estimated $5.93M sold.

Michael Gelband first reported a position in RPRX in Q2 2020 and held it in 14 quarters. The position peaked at $14.9M in Q2 2023. 640 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Michael Gelband reported no remaining Royalty Pharma position as of Q2 2026 after selling out during the quarter.
  • Michael Gelband sold 123,562 Royalty Pharma shares in Q2 2026, an estimated $5.93M.
  • Michael Gelband first reported a position in Royalty Pharma in Q2 2020 and held it in 14 quarters.
  • Michael Gelband's Royalty Pharma position peaked at $14.9M in Q2 2023.
  • 640 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.